Measurement of the 11C-flumazenil binding in the visual cortex predicts the prognosis of hemianopia.
In order to determine whether functional neuroimaging studies can predict the prognosis of hemianopia due to organic cerebral disorders, we studied 8 patients (6 men and 2 women; age, 56.0+/-8.6 years) with homonymous hemianopia and compared them with 15 normal subjects (6 men and 9 women; age, 54.3+/-4.4 years). The cerebral glucose metabolism and 11C-flumazenil (FMZ) binding were measured by positron emission tomography, more than 1 month after the onset of the condition. Bilateral regions of interest (ROIs) were selected in the striate cortex, extrastriate cortex, cuneus and thalamus. Further, semi-quantitative data on the cerebral glucose metabolism and FMZ binding were obtained for the ROIs and compared with the data obtained for homologous regions in the contralateral hemisphere by calculating the ipsilateral/contralateral (I/C) ratio. The I/C ratios for the cerebral glucose metabolism and FMZ binding in the striate cortex were significantly low in the patients (glucose metabolism, P<0.0005; FMZ binding, P<0.005), while the ratio for the FMZ binding in the cuneus increased (P<0.0005). We observed that 5 patients, whose I/C ratio for the FMZ binding in the striate cortex was >0.850, experienced an improvement in their visual field, while that 3 patients with lower I/C ratios did not. The FMZ-PET may be useful to predict the prognosis of hemianopia in the chronic phase.